Posted by Michael Wonder on 04 Dec 2020
Novo Nordisk files for US FDA regulatory approval of once-weekly semaglutide 2.4 mg for weight management
4 December 2020 - Novo Nordisk today announced the submission of a new drug application to the US FDA for subcutaneous semaglutide 2.4 mg, a once-weekly glucagon-like peptide-1 (GLP-1) analogue for chronic weight management.
A priority review voucher has been applied to the new drug application, leading to an anticipated review time of six months from the submission date, according to standard FDA review timelines.
